Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma.

about

Approach to Cutaneous Lymphoid Infiltrates: When to Consider Lymphoma?Sézary Syndrome: Clinical and Biological Aspects.

P2860

Q26741951-7006C8D8-AEA0-439A-A9FD-D06AA117666E Q38814744-1E900506-AF4A-4D72-A82E-B87637032323

P2860

Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma.

Item

http://www.wikidata.org/entity/Q38286313

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma.

@en

type

Item

label

Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma.

@en

prefLabel

Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma.

@en

P1476

Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma.

@en

P2093

Bláithín Moriarty

http://www.w3.org/2001/XMLSchema#string

Sean Whittaker

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results

Usage of human T-cell receptor V beta, J beta, C beta, and V alpha gene segments is not proportional to gene number.

Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies.

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins.

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.

P304

159-171

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17474086.2015.984681

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25495961

http://www.w3.org/2001/XMLSchema#string

Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma.

about

P2860

P2860

Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698